Adverum Biotech

ADVM

Current ValuationThe current P/E ratio is -0.52, within the reasonable range, cheaper than 36.22% of the time in the past 5 years, and the industry ranks 136/605, the industry Median -1.93.

-0.521xP/E
Stock price--

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-59.90x150.60%$194.07B
MRNAUSModerna
-30.67x15.63%$96.65B
CSLLYUSCSL Limited
-25.62x--$66.07B
NTRAUSNatera
-304.20x6.85%$58.51B
RVMDUSRevolution Medicines
-23.82x62.08%$42.13B
ROIVUSRoivant Sciences
-94.74x146.49%$25.22B
BNTXUSBioNTech SE
-11.72x19.35%$22.90B
INSMUSInsmed
-23.87x75.01%$20.89B
BBIOUSBridgebio Pharma
-19.09x28.60%$13.21B
SMMTUSSummit Therapeutics
-14.99x20.65%$12.84B
MDGLUSMadrigal Pharma
-33.23x51.30%$10.80B
PCVXUSVaxcyte
-9.79x47.91%$10.42B
KYMRUSKymera Therapeutics
-31.49x5.24%$9.43B
TWSTUSTwist Bioscience
-68.71x28.71%$9.39B
IBRXUSImmunityBio
-9.37x151.32%$9.29B
CYTKUSCytokinetics
-9.94x6.85%$8.89B
ARWRUSArrowHead Pharma
-26.01x35,923.70%$8.32B
ABVXUSAbivax SA
-17.36x22.99%$8.07B
SYREUSSpyre Therapeutics
-53.65x45.60%$8.06B
IONSUSIonis Pharma
-13.35x51.03%$7.54B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.